Physician profile
Lynn Lang
NPI 1942399050
$13,856.14
in general payments reported to CMS, 2019-2025
58 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,940 · 2020: $2,023 · 2021: $2,072 · 2022: $1,592 · 2023: $2,820 · 2024: $1,793 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,215 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,215.03 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,571.64 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $1,956.45 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,109.15 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amarin Pharma, INC. | $745.19 | 2019-2023 | |
| Glaxosmithkline, LLC. | $594.92 | 2019-2025 | Trelegy Ellipta |
| Allergan, INC. | $489.85 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $478.04 | 2019-2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $474.94 | 2019-2025 | Rexulti, Abilify Mycite |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.79 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $377.74 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Janssen Pharmaceuticals, INC | $359.66 | 2020-2023 | Xarelto |
| Novo Nordisk INC | $345.43 | 2019-2025 | Rybelsus, Ozempic |
| Corcept Therapeutics | $295.25 | 2019-2023 | Korlym |
| Sanofi-Aventis U.S. LLC | $263.92 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $247.83 | 2019-2025 | Trintellix |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.